In vitro activity of amphotericin B against Aspergillus terreus isolates from different countries and regions

Journal of Chemotherapy

Volumn 20, Issue 6, 2008, Pages 756-757

  Tortorano, Anna Maria ^a   Prigitano, A ^a   Dho, G ^a   Biraghi, E ^a   Stevens, D A ^b   Ghannoum, M ^c,d   Nolard, N ^e   Viviani, M A ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS TERREUS; CONIDIUM; CONTROLLED STUDY; EUROPE; FUNGUS ISOLATION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NAIL; NONHUMAN; RESPIRATORY SYSTEM; UNITED STATES;

EID: 59349103572     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.6.756     Document Type: Article

References (11)

1. Herbrecht R, Fluckiger U, Gachot B, Ribaud P, Thiebaut A, Cordonnier C. Treatment of invasive Candida and invasive Aspergillus infections in adult haematological patients. Eur J Cancer Supplements 2007; 5: 49-59.
2. Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360.
3. Steinbach W, Benjamin D, Kontoyiannis D, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192-198.
4. Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201-207.
5. Sutton DA, Sanchie SE, Revankar SG, Fothergill AW, Rinaldi MG. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J Clin Microbiol 1999; 37: 2343-2345.
6. Pfaller MA, Messer SA, Hollis RJ, Jones RN, and the SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2002; 46: 1032-1037.
7. Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 2000; 49: 601-606.
8. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Anti-fungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3715-3719.
9. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. NCCLS document M38-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
10. Lass-Förl C, Griff K, Kontoyiannis D. Molecular typing of Aspergillus terreus isolates collected in Houston, Texas, and Innsbruck, Austria: evidence of great genetic diversity. J Clin Microbiol 2007; 45: 2686-2690.
11. Balajee SA, Houbraken J, Verweji P, Hong SB, Yaghuchi T, Varga J, Samson RA. Aspergillus species identification in the clinical setting. Studies Mycol 2007; 59: 39-46.